
51 - 200 employees
Founded 2019
🏥 Healthcare
🧬 Biotechnology
💊 Pharmaceuticals
💰 $175.3M Post IPO equity on 2024-03
Healthcare • Biotechnology • Pharmaceuticals
NewAmsterdam Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular disease and other lipid-related conditions. The company is advancing obicetrapib, a CETP inhibitor, and other programs aimed at lowering LDL-C and reducing cardiovascular risk for patients who have unmet needs despite existing lipid-lowering treatments. NewAmsterdam emphasizes science-backed development, clinical trials, and patient-focused initiatives.
Selected: 🆕 Date Added.
🕒 3 days ago
Global Regulatory Affairs executive leading US and international drug development strategies at NewAmsterdam Pharma. Directing submissions, launch readiness, post-approval lifecycle management, and regulatory teams.
🇺🇸 United States – Remote
💰 $175.3M Post IPO equity on 2024-03
⏰ Full Time
🟠 Senior
👔 Vice President
👻 Ghost score 10%